Logo image of VRDN

VIRIDIAN THERAPEUTICS INC (VRDN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VRDN - US92790C1045 - Common Stock

32.31 USD
-0.26 (-0.8%)
Last: 12/12/2025, 8:06:51 PM
32.31 USD
0 (0%)
After Hours: 12/12/2025, 8:06:51 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to VRDN. VRDN was compared to 531 industry peers in the Biotechnology industry. The financial health of VRDN is average, but there are quite some concerns on its profitability. VRDN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRDN has reported negative net income.
VRDN had a negative operating cash flow in the past year.
VRDN had negative earnings in each of the past 5 years.
VRDN had a negative operating cash flow in each of the past 5 years.
VRDN Yearly Net Income VS EBIT VS OCF VS FCFVRDN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

VRDN has a Return On Assets (-52.32%) which is in line with its industry peers.
VRDN's Return On Equity of -60.04% is fine compared to the rest of the industry. VRDN outperforms 61.02% of its industry peers.
Industry RankSector Rank
ROA -52.32%
ROE -60.04%
ROIC N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
VRDN Yearly ROA, ROE, ROICVRDN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRDN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRDN Yearly Profit, Operating, Gross MarginsVRDN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

6

2. Health

2.1 Basic Checks

VRDN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRDN has more shares outstanding
VRDN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VRDN has an improved debt to assets ratio.
VRDN Yearly Shares OutstandingVRDN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRDN Yearly Total Debt VS Total AssetsVRDN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

An Altman-Z score of 21.52 indicates that VRDN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 21.52, VRDN belongs to the top of the industry, outperforming 90.02% of the companies in the same industry.
VRDN has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
VRDN has a Debt to Equity ratio of 0.04. This is comparable to the rest of the industry: VRDN outperforms 40.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 21.52
ROIC/WACCN/A
WACC8.82%
VRDN Yearly LT Debt VS Equity VS FCFVRDN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

VRDN has a Current Ratio of 11.28. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VRDN (11.28) is better than 85.12% of its industry peers.
VRDN has a Quick Ratio of 11.28. This indicates that VRDN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VRDN (11.28) is better than 85.12% of its industry peers.
Industry RankSector Rank
Current Ratio 11.28
Quick Ratio 11.28
VRDN Yearly Current Assets VS Current LiabilitesVRDN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 25.52% over the past year.
The Revenue has grown by 23340.07% in the past year. This is a very strong growth!
Measured over the past years, VRDN shows a very negative growth in Revenue. The Revenue has been decreasing by -41.64% on average per year.
EPS 1Y (TTM)25.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.43%
Revenue 1Y (TTM)23340.07%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%81958.14%

3.2 Future

The Earnings Per Share is expected to grow by 20.75% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 397.69% on average over the next years. This is a very strong growth
EPS Next Y-4.7%
EPS Next 2Y0.88%
EPS Next 3Y14.42%
EPS Next 5Y20.75%
Revenue Next Year24826.4%
Revenue Next 2Y1527.21%
Revenue Next 3Y909.35%
Revenue Next 5Y397.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VRDN Yearly Revenue VS EstimatesVRDN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
VRDN Yearly EPS VS EstimatesVRDN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRDN. In the last year negative earnings were reported.
Also next year VRDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRDN Price Earnings VS Forward Price EarningsVRDN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRDN Per share dataVRDN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as VRDN's earnings are expected to grow with 14.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.88%
EPS Next 3Y14.42%

More info and screens

0

5. Dividend

5.1 Amount

VRDN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

VIRIDIAN THERAPEUTICS INC

NASDAQ:VRDN (12/12/2025, 8:06:51 PM)

After market: 32.31 0 (0%)

32.31

-0.26 (-0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-25 2026-02-25/amc
Inst Owners99.08%
Inst Owner Change-1.84%
Ins Owners0.04%
Ins Owner Change0%
Market Cap3.08B
Revenue(TTM)70.79M
Net Income(TTM)-301.97M
Analysts85
Price Target40.62 (25.72%)
Short Float %10.09%
Short Ratio6.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.05%
Min EPS beat(2)2.88%
Max EPS beat(2)69.21%
EPS beat(4)4
Avg EPS beat(4)22.3%
Min EPS beat(4)2.88%
Max EPS beat(4)69.21%
EPS beat(8)5
Avg EPS beat(8)8.49%
EPS beat(12)7
Avg EPS beat(12)-1.64%
EPS beat(16)9
Avg EPS beat(16)-3.19%
Revenue beat(2)2
Avg Revenue beat(2)101999%
Min Revenue beat(2)68.49%
Max Revenue beat(2)203929%
Revenue beat(4)4
Avg Revenue beat(4)51014.2%
Min Revenue beat(4)0.65%
Max Revenue beat(4)203929%
Revenue beat(8)5
Avg Revenue beat(8)25508.3%
Revenue beat(12)5
Avg Revenue beat(12)16989.2%
Revenue beat(16)7
Avg Revenue beat(16)12756.5%
PT rev (1m)2.11%
PT rev (3m)2.44%
EPS NQ rev (1m)-5.43%
EPS NQ rev (3m)-0.44%
EPS NY rev (1m)7.42%
EPS NY rev (3m)-6.34%
Revenue NQ rev (1m)20389.8%
Revenue NQ rev (3m)26564.1%
Revenue NY rev (1m)61651.7%
Revenue NY rev (3m)55218.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 43.56
P/FCF N/A
P/OCF N/A
P/B 6.13
P/tB 6.13
EV/EBITDA N/A
EPS(TTM)-3.21
EYN/A
EPS(NY)-3.89
Fwd EYN/A
FCF(TTM)-3.42
FCFYN/A
OCF(TTM)-3.42
OCFYN/A
SpS0.74
BVpS5.27
TBVpS5.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.32%
ROE -60.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.23%
ROA(5y)-47.6%
ROE(3y)-42.28%
ROE(5y)-52.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 79.7%
Cap/Sales 0.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.28
Quick Ratio 11.28
Altman-Z 21.52
F-Score2
WACC8.82%
ROIC/WACCN/A
Cap/Depr(3y)191.45%
Cap/Depr(5y)174.87%
Cap/Sales(3y)166.8%
Cap/Sales(5y)103.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.43%
EPS Next Y-4.7%
EPS Next 2Y0.88%
EPS Next 3Y14.42%
EPS Next 5Y20.75%
Revenue 1Y (TTM)23340.07%
Revenue growth 3Y-53.27%
Revenue growth 5Y-41.64%
Sales Q2Q%81958.14%
Revenue Next Year24826.4%
Revenue Next 2Y1527.21%
Revenue Next 3Y909.35%
Revenue Next 5Y397.69%
EBIT growth 1Y-15.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.51%
EBIT Next 3Y11%
EBIT Next 5Y36.92%
FCF growth 1Y-80.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-80.88%
OCF growth 3YN/A
OCF growth 5YN/A

VIRIDIAN THERAPEUTICS INC / VRDN FAQ

What is the fundamental rating for VRDN stock?

ChartMill assigns a fundamental rating of 3 / 10 to VRDN.


What is the valuation status for VRDN stock?

ChartMill assigns a valuation rating of 0 / 10 to VIRIDIAN THERAPEUTICS INC (VRDN). This can be considered as Overvalued.


How profitable is VIRIDIAN THERAPEUTICS INC (VRDN) stock?

VIRIDIAN THERAPEUTICS INC (VRDN) has a profitability rating of 1 / 10.


How financially healthy is VIRIDIAN THERAPEUTICS INC?

The financial health rating of VIRIDIAN THERAPEUTICS INC (VRDN) is 6 / 10.


Can you provide the expected EPS growth for VRDN stock?

The Earnings per Share (EPS) of VIRIDIAN THERAPEUTICS INC (VRDN) is expected to decline by -4.7% in the next year.